Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

The Medtronic Harmony transcatheter pulmonary valve (TPV) system offers a less invasive treatment option for patients with a congenital heart defect irregularity in their right ventricular outflow tract (RVOT) that requires a pulmonary valve placement to restore valve function.

Feature | Structural Heart | Dave Fornell, Editor

One-year Results of the Harmony Transcatheter Pulmonary Valve Trial Presented at SCAI 2021

April 30, 2021 — New study results validate the effectiveness of the Medtronic Harmony transcatheter pulmonary valve ...

April 30, 2021

The two FDA-clear transcatheter aortic valve replacement (TAVR) valves on the market, the Edwards Lifesciences Sapien 3 (left) and the Medtronic CoreValve (right).

Feature | Structural Heart

TAVR Access is Inequitable Based Socioeconomics Level and Geography

April 30, 2021 – An analysis of growth patterns in transcatheter aortic valve replacement (TAVR) programs across United ...

April 30, 2021

New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell

News | Cath Lab

Young African Americans With Coronary Disease Impacted by Non-traditional Risk Factors

April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American ...

April 29, 2021

The Abiomed Impella percutaneous heart pump was shown in the NCSI study to greatly improve survival of acute myocardial infarction with cardiogenic shock (AMICS), raising survival from 50 percent to 71 percent. Ambulance image from Getty Images.

Feature | Cardiogenic Shock | By Dave Fornell, Editor

National Cardiogenic Shock Initiative Protocol Shows 71 Percent Survival

April 29, 2021 — The results of a large, national heart attack study show that patients with cardiogenic shock survived ...

April 29, 2021

A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today.

News | Antiplatelet and Anticoagulation Therapies

Long-term Dual Antiplatelet Therapy Benefits Reinforced in SCAI Late-breaking Study

April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term, dual-antiplatelet ...

April 28, 2021

The STAT2 trial used a combination of the Biolife Statseal potassium ferrate hemostatic patch and a Terumo TR Band to reduce radial access arteriotomy site hemostasis by 50 percent.

News | Radial Access | Dave Fornell, Editor

Radial Hemostasis Time Cut by 50 Percent With StatSeal in Combination With TR Band

April 28, 2021 — A new study reveals the use of a potassium ferrate hemostatic patch (PFHP) reduces the time to ...

April 28, 2021

Videos | Cardiogenic Shock

VIDEO: Final Results of the National Cardiogenic Shock Initiative Show 71 Percent Survival

William O’Neill, M.D., medical director of the Center for Structural Heart Disease at Henry Ford Hospital, Detroit ...

April 28, 2021

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images

News | Cath Lab

COVID Caused Major Decline in Heart Attack Patients Seeking Care

April 28, 2021 – Results from a retrospective observational study, presented today at Society for Cardiovascular ...

April 28, 2021

Patients receiving an implantable cardioverter defibrillator (ICD) should be regularly screened for anxiety and depression, according to research presented at European Heart Rhythm Association (EHRA) 2021 conference. ICD depression

News | EP Lab

Study Shows Risks of Anxiety and Depression After Cardiac Device Implantation

April 26, 2021 — Patients receiving an implantable cardioverter defibrillator (ICD) should be regularly screened for ...

April 26, 2021

Racism and heart disease. This study looks at heart failure patients and the impact of socioeconomic disparities associate with epigenetics. The study looks to overcome preconcieved ideas about race in cardiac studies by looking at underlaying causes for the disease. Image courtesy of the American Journal of Physiology

News | Heart Failure

Socioeconomic Disparities Associate With Epigenetics and Heart Failure Outcomes

April 26, 2021 – Cardiovascular diseases are the leading cause of death in the United States. Heart failure disproportio ...

April 26, 2021

News

North American COVID-19 STEMI Research Reveals High Mortality and Atypical Symptoms

April 20, 2021 – The Minneapolis Heart Institute Foundation (MHIF) announced the first publication of outcomes from the ...

April 20, 2021

The reSept ASD Occluder is the first structural heart occluder with a metal-free, bioresorbable frame. The novel implant is designed to overcome the limitations of current transcatheter occluders. It is hoped the design will reduce the risk of complications associated with the long-term presence of metal in the heart and to preserve future treatment options requiring transseptal intervention.

News | Structural Heart Occluders

Bioresorbable ASD Occluder Prepares to Enter U.S. Clinical Trial

April 20, 2021 — Start-up medical device company atHeart Medical announced it is initiating its U.S. investigational ...

April 20, 2021

The Elixer Dynamx Coronary Bioadaptor Stent technology uses a bioresorbable polymer that dissolves after three months and disconnected joints between numerous stent segments, allowing it to articulate and share to the vessel and movement.

News | Stents

First Patient Treated in Elixer Dynamx Coronary Bioadaptor Stent Technology

April, 14, 2021 – Elixir Medical recently announced the first patient was treated in the BIOADAPTOR randomized ...

April 14, 2021

COVID-19 disrupted all aspects of science and medicine and unmasked striking disparities and opportunities for transformation. Coronavirus impact this past year is expected to result in a massive rise in new cases of chronic health conditions, including cardiolvascular disease and heart failure.

News | Coronavirus (COVID-19)

Tsunami of Chronic Health Conditions Expected Due to COVID-19 Disruption of Healthcare

April 6, 2021 — A tsunami of chronic health conditions as a result of the COVID-19 (SARS-CoV-2) pandemic, especially car ...

April 07, 2021

The Acutus Medical AcQBlate Force sensing ablation catheter.

News

Acutus Medical Initiates First IDE Therapy Trial With AcQBlate Force Sensing Ablation System

April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter ...

April 05, 2021